Comparison on Therapeutic Efficacy of Combined TP or PF with Concurrent Radiotherapy to Advanced Esophageal Carcinoma

Objective To investigate the therapeutic efficacy and adverse reactions of combined Cisplatin and Paclitaxel (TP regimen) or Fluorouracil (PF regimen) with the synchronous radiotherapy to the advanced esophageal carcinoma . MethodsSeventy-two cases with esophageal carcinoma were randomly assigned in TPregimen and PF regimen groups.All the patients received conventional radiotherapy at a total dose of 60～66 Gy (in 30~33 fractions).In TPregimen group,the patients received intravenous infusion of Paclitaxel (135～165 mg/m²) for 3h on day 1 and DDP(20～30 mg/m² daily) on days 1～3,with every 21 days as one cycle.PF regimen consisted of cisplatin (20～30 mg/m2) on days 1～3 and of continuous intravenous infusion of fluorouracil (500 mg/m²) for 5 days,with every 21 days as one cycle. Results No significant differences were found in the survival rates of 1 and 3 years between the TP regimen group (86% and 53%,respectively ) and PF regimen group (83% and 50%,respectively)(χ²=0.148,P=0.701),The same result was also found in the short-term effect.No marked differences of the incidence of all adverse reactions including radiotherapy-induced esophagitis,gastrointestinal reactions and myelosuppression were observed between the two groups(P>0.05). Conclusion Compared with the treatment of esophageal carcinoma using PF regimen,the treatment of esophgeal carcinoma using TP regimen shows the closed therapy efficacy and doesn′t increase the adverse reactions.